Figures computed from official regulatory filings — .
Analysttarget 8 USD (-48%)
Ownershipinsiders 27.11% · institutions 78.53% · short 0.9% of float · 2.05d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Rallybio Corp only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Market information source · Nov 16, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Nov 16, 2026
Purchases and sales · full history
31 buys16 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| MACKAY MARTIN | Exercise | $8.5K | Unusual size | SEC | |
| MACKAY MARTIN | ExerciseD (derivative) | $65K | Unusual size | SEC | |
| MACKAY MARTIN | Exercise | $80.3K | Unusual size | SEC | |
| MACKAY MARTIN | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | Unusual size | SEC | |
| HUNT RONALDtrack record | ExerciseD (derivative) | $51.5K | SEC | ||
| MACKAY MARTIN | ExerciseD (derivative) | $65K | Unusual size | SEC | |
| HUNT RONALDtrack record | Exercise | $63.7K | SEC | ||
| MACKAY MARTIN | Exercise | $88.2K | Unusual size | SEC | |
| Lieber Jonathan I | Exercise | $106K | Unusual size | SEC | |
| Lieber Jonathan I | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| HUNT RONALDtrack record | Exercise | $31.5K | SEC | ||
| HUNT RONALDtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| HUNT RONALDtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| HUNT RONALDtrack record | ExerciseD (derivative) | $51.5K | SEC | ||
| Lieber Jonathan I | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Lieber Jonathan I | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| HUNT RONALDtrack record | Exercise | $69.9K | SEC | ||
| HUNT RONALDtrack record | Exercise | $8.5K | SEC | ||
| Lieber Jonathan I | Exercise | $117.2K | Unusual size | SEC | |
| Lieber Jonathan I | Exercise | $82.6K | Unusual size | SEC | |
| Nash Christine A | Exercise | $8.5K | SEC | ||
| Nash Christine A | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Uden Stephen | Exercise | $202.1K | SEC | ||
| Uden Stephen | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Chung Wendy | Exercise | $31.5K | SEC |